Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » .11 and Up! » Pacific Therapeuitcs - A Clinical Stage Company » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
djk  - posted
Fyi,

This company uses FDA apporved drugs and other compaounds and is at clinical stage testing.

NOTE: Only on the CNSX Symbol: PT
__________________________________________________


Pacific Therapeutics Corporation (PT: CNSX) a Specialty Pharmaceutical Company is focused on the identification, development and sales of drug candidates to treat diseases of the liver and lungs caused by excessive and progressive tissue scarring, called fibrosis.

Pacific Therapeutics’ business and drug development strategy reduces risk, time and the capital costs of developing new drug therapies for liver and lung diseases caused by fibrosis. By combining existing approved drugs that have already known safety and toxicity profiles, the company eliminates the inherent risks involved with basic pre clinical research and animal testing.

Pacific Therapeutics’ lead drug candidate; PTL-202 is set for Phase 1 clinical trials in 2012. PTL-202 is a combination of drugs that have been approved by the FDA to treat diseases other than fibrosis. PTL-202 is being developed by Pacific Therapeutics to treat a progressive lung scarring disease, named Idiopathic Pulmonary Fibrosis (IPF). More people die of annually IPF than either prostate or breast cancer. IPF is estimated to be a $2 billion market opportunity.

The once a day tablet of PTL-202 uses the multi-layer technology developed by IntelGenx Corp. of Montreal. The multi-layer technology has been identified as an excellent fit to provide different release profiles of the Active Ingredients, and establishing blood levels of the Active Ingredients which is designed to maximize their efficacy.

On July 12, 2011 Pacific Therapeutics engaged CRBIO (Clinical Research and Biosciences http://www.crbio.co.in/ of Hyderabad, India to conduct a clinical trial with PTL-202 in a drug to drug interaction study in humans. CRBIO is the clinical trials a division of RA Chem Pharma Limited., India. http://www.rachempharma.com/

Pacific Therapeutics’ second drug candidate, PTL-303, is also a combination of drugs, one of which has been approved for human use in Japan. PTL-303 has been shown to be effective in the reduction of molecules that contribute to the development of diseases including, liver cirrhosis in humans. PTL-303 may be developed as a treatment to reduce the severity of progressive diseases like chronic liver disease.

Chronic liver disease which may lead to cirrhosis of the liver is responsible for over 1.4m deaths annually (WHO, World Health Report 2004) In the US chronic liver disease is among the top ten disease related causes of death (CDC, National Center for Health Statistics, 2004). This market is estimated to be $3.0 billion.


Shares issued: 20,787,950
Escrowed shares: 10,031,001
Warrants & Optiions: 4,653,000
Fully Diluted: 25,440,950

52 wk hi-lo: 0.25-0.10


Website: http://www.pacifictherapeutics.com/
 
djk  - posted
News Release

PACIFIC THERAPEUTICS LTD. TO EXHIBIT AT
VANCOUVER SMALL-CAP CONFERENCE

VANCOUVER, BRITISH COLUMBIA- (March 29, 2012) – Pacific Therapeutics Ltd. (PT.CNSX) (the “company”) is pleased to announce that it has been accepted as an exhibitor at the Vancouver Small-Cap Conference to be held on April 10, 2012 at the Vancouver Convention Center.

Pacific Therapeutics Ltd is a clinical stage specialty pharmaceutical company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis).

The company’s lead drug candidate PTL-202 is a combination of Pentoxifylline (a FDA approved drug used for treating intermittent claudication) and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant. PTL-202 is currently being reviewed for initial trials in humans which are expected to commence in 2012.

The Small-Cap Conferences are informative one-day events with 2-3 prominent guest speakers and up to 9 brief corporate presentations from a variety of quality, small-cap Canadian companies.


ABOUT PACIFIC THERAPEUTICS LTD.

TheCompany’s strategy includes reformulating approved drugs to increase efficacy and patient compliance, completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies for fibrosis by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles. The company’s lead drug candidate is PTL-202 a combination of approved drugs focused on treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.


FORWARD LOOKING STATEMENTS

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Readers should not place undue reliance on the Company’s forward-looking statements, as the Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company’s business, or if the Company’s estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

On Behalf of the Board of Directors
/s/ Doug Unwin

Douglas H. Unwin, CEO & President
(604) 738-1049

unwin@pacifictherapeutics.com

www.pacifictherapeutics.com
 
djk  - posted
News Release



PROGRESS OF CLINICAL DEVELOPMENT





VANCOUVER, BRITISH COLUMBIA- (April 10, 2012) – Pacific Therapeutics Ltd. (PT.CNSX) (the “Company”) is pleased to provide an update on the progress of the clinical development of PTL-202.



As previously announced the Company has engaged CRBIO of India to conduct a drug drug interaction study of PTL-202 and its components.



CRBio has submitted the PTL-202 drug-drug interaction clinical trial protocol to the Central Drugs Standard Control Organization Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi, India.



The clinical study protocol is currently being reviewed by the Central Drugs Standard Control Organization (India’s pharmaceutical regulatory authority). The study will be conducted once this regulatory approval is received, which is expected this quarter.



The study protocol calls for dosing of 12 normal healthy adult males. This an open label, non randomized, three treatment, three period single dose study. Once enrolment is completed the study should only take 1 month to complete. The lack of any drug drug interaction will be a positive result and signal the continued clinical development of PTL-202.



CRBio is 'full service' contract research organization. It is set up in a centrally located area in Hyderabad India. The facility is spread over 20,000 sq.ft. in well laid out areas with operations such as Clinical, Bioanalytical, Pharmacokinetic & Statistical, QA & RA, QC. With 4 full time doctors plus paramedical staff, clinics consist of 72 beds and CRBio has a 3,000 volunteer database and a state of the art bioanalytical laboratory. CRBio as an independent contractor has completed over 150 BA/BE (Bioavailability Bioequivalence) projects similar to the PTL-202 drug drug interaction study.





ABOUT PACIFIC THERAPEUTICS LTD.



Pacific Therapeutics Ltd is a clinical stage specialty pharmaceutical company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis).



The company’s lead drug candidate PTL-202 is a combination of Pentoxifylline (a FDA approved drug used for treating intermittent claudication) and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant. PTL-202 is currently being reviewed for initial trials in humans which are expected to commence in 2012. PTL-202 a combination of approved drugs focused on treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.



The Company’s strategy includes reformulating approved drugs to increase efficacy and patient compliance, completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies for fibrosis by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.


www.pacifictherapeutics.com
 
BooDog  - posted
I still haven't been able to get a quote on this one. Tried the PT.CNSX, PT by itself, yahoo - There are no All Markets results for pacific therapeutics.
I have the same issues sometimes trying to find Italian equivalents too and then when I do the house wants a small fortune to play them!
[Eek!]

[Wall Bang]
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share